F-star Therapeutics, Inc.

Kymab Limited

Invox Pharma Limited

F-star Delta Limited

Mustapha Faroudi

Mihriban Tuna

Francisca Wollerton Van Horck

Jamie Iain Campbell

Fadi Badr

Ryan Fiehler

Frederick Akele

Nikole Sandy

Matthew John McCourt

Miguel Gaspar

Richard Charles Alfred Sainson

Stephen John Arkinstall

Katy Louise Everett

Matthew Kraman

Katarzyna Kmiecik

Natalie Fosh

Cyril Privezentzev

Barbara Hebeis

Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.

Bispecific antibody for ICOS and PD-L1

The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.

FC binding fragments comprising a PD-L1 antigen-binding site

The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.

Binding molecules binding PD-L1 and LAG-3

Growing community of inventors

Cambridge, United Kingdom

Mustapha Faroudi